bioMerieux, Inc. NUCLISENS easyMAG Magnetic Silica, REF 280133, 24 x 1.2mL bottles/kit. Recall
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
NUCLISENS easyMAG Magnetic Silica, REF 280133, 24 x 1.2mL bottles/kit.
Brand
bioMerieux, Inc.
Lot Codes / Batch Numbers
Lot numbers distributed in the U.S.: Z012MK1MS, exp. 28-NOV-2022, Z012ML1MS, exp. 28-NOV-2022, Z012NB1MS, exp. 28-DEC-2022, Z013AL1MS, exp. 28-JAN-2023. UDI: 03573026139339.
Products Sold
Lot numbers distributed in the U.S.: Z012MK1MS, exp. 28-NOV-2022; Z012ML1MS, exp. 28-NOV-2022; Z012NB1MS, exp. 28-DEC-2022; Z013AL1MS, exp. 28-JAN-2023. UDI: 03573026139339.
bioMerieux, Inc. is recalling NUCLISENS easyMAG Magnetic Silica, REF 280133, 24 x 1.2mL bottles/kit. due to There is a potential of no result leading to possible delayed result due to contamination of extraction reagents.. Based on FDA medical device recall database.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
There is a potential of no result leading to possible delayed result due to contamination of extraction reagents.
Recommended Action
Per FDA guidance
The recalling firm issued undated letters with a reference number of FSCA#5690 via overnight mail on 7/20/2022. The letter explained the issue and instructed the customers to distribute the information to all appropriate personnel in their laboratory and forward the information to all parties that may use the product, including others to whom the customer may have transferred the product. They are informed they can continue to use the impacted lots of the NUCLISENS Magnetic Silica Ref 280133 listed in Table 1 except for bacterial nucleic acid detection applications, especially Legionella spp, and other applications such as 16S rDNA, 23S rDNA. The recalling firm confirms that all applications for which the negative controls are valid can be safely performed. If the customer is encountering invalid negative controls, they are to stop using it and discard the impacted lot and contact the bioMerieux representative to order lots not concerned by the issue. Based on benefit/risk analysis and to avoid product backorder, the customer is informed that for a short period of time, they may receive some of the lots listed in Table 1 of the letter with an insert that will contain the same information and actions required as previously mentioned. An Acknowledgement Form was enclosed for return to confirm receipt of the notice. The letter listed all lot numbers globally distributed, but the customers in the U.S. only received lot numbers Z012MK1MS, Z012ML1MS, Z012NB1MS, and Z013AL1MS. The U.S. customers could receive other lots listed in the letter at a later time.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticeDistribution
As reported by FDA
AZ, AR, CA, CT, FL, IL, IN, KS, KY, MD, MA, MI, MN, MO, MT, NJ, NY, NC, OH, OR, PA, TN, TX, VA
Page updated: Jan 10, 2026